We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea. These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed. The fidaxomicin labeling was revised to include information about the possibility of hypersensitivity reactions.
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Fidaxomicin is a macrolide antibacterial drug that was approved in the US for the treatment of Clostridium difficileassociated diarrhea (CDAD) in May 2011. The approved dosing regimen for fidaxomicin tablets is 200 mg taken orally twice daily. Fidaxomicin has a larger macrolide ring than other macrolides. Fidaxomicin has an 18-member carbon ring, whereas other drugs in this group have 14-, 15-, or 16-member rings. The main route of fidaxomicin metabolism is conversion to the primary metabolite OP-1118. The drug is minimally absorbed; maximal plasma concentrations of fidaxomicin and OP-1118 are in the nanograms per milliliter range [1] .
Although no specific concerns related to hypersensitivity reactions were identified during the drug development hypersensitivity reactions associated with fidaxomicin use have been reported to the Food and Drug Administration (FDA) in the postmarketing period. After receiving these reports, we conducted a review of the FDA Adverse Event Reporting System and the literature.
We identified 12 cases; 11 were spontaneously reported (ie, voluntarily reported to the FDA by health care professionals), and 1 was reported in the literature [2] . The cases are summarized in Table 1 . A history of macrolide allergy was reported in 3 of 12 cases. No concomitant medications were listed in the reports for 8 cases. Review of the concomitant medications in 4 cases implicated fidaxomicin as the most probable explanation for hypersensitivity reactions.
In the 12 cases of fidaxomicin hypersensitivity evaluated, 6 patients reported facial, tongue, or throat swelling, 4 reported a diffuse rash, 1 reported a burning sensation in the throat, and the patient described in the literature [2] had a purpuric rash on the lower extremities. The time to onset after first receiving fidaxomicin to a hypersensitivity event ranged from 1 hour to 7 days. Hypersensitivity reactions resolved in 10 cases; 9 events resolved after discontinuation of fidaxomicin, and the other event also resolved, but the report did not clearly indicated whether fidaxomicin was discontinued. In 1 case where fidaxomicin was continued along with diphenhydramine, rash and itching persisted. The outcome was unknown in 1 case.
Two patients reported a positive rechallenge to fidaxomicin. In the first rechallenge case, the patient experienced tongue and facial swelling and dyspnea on the 5th day of fidaxomicin treatment, approximately 9 hours after fidaxomicin intake. The symptoms resolved after administration of antihistamines and intravenous hydrocortisone. When the patient restarted fidaxomicin the next day, he experienced facial and tongue swelling shortly after taking the drug. In the second rechallenge case, the patient experienced swelling of the throat that resolved after the discontinuation of fidaxomicin. She experienced a similar reaction when she was treated again with fidaxomicin for recurrent CDAD 1 month later.
A literature report [2] described a 79-year-old man who developed purpuric rash on the lower extremities on day 7 of fidaxomicin administration. A skin biopsy of this patient's rash was consistent with a delayed type 4 hypersensitivity reaction.
Based on the information described above, the contraindications, warnings and precautions, and adverse reactions sections of the fidaxomicin labeling were revised in March 2013 [1] . Known hypersensitivity to fidaxomicin is listed as a contraindication for fidaxomicin use. The warnings and precautions section provides information about acute hypersensitivity reactions, including dyspnea and angioedema, which may be associated with fidaxomicin. The warning also indicates that a history of macrolide allergy should be taken into consideration when prescribing fidaxomicin, given that 3 of the 12 patients reported a history of macrolide allergy.
Interestingly, allergic reactions have been reported in the treatment of CDAD, including anaphylaxis after administration of oral vancomycin, another minimally absorbed drug [3, 4] . It has been suggested that colonic inflammation in the case of C. difficile infection can significantly increase the bioavailability of the drug. It has been also hypothesized that in a predisposed patient a minimal systemic exposure or even contact with inflamed mucosa could be sufficient to cause an allergic reaction. In conclusion, the described events are consistent with hypersensitivity reactions associated with fidaxomicin use. The 2 cases of positive rechallenge support this association. Because fidaxomicin is minimally absorbed, such adverse reactions are not expected and may not be considered especially in a patient with multiple concomitant medications. Healthcare providers should be aware of the risk of hypersensitivity reactions with fidaxomicin. It is also important that these adverse reactions be reported to the FDA MedWatch program (http://www.fda.gov/ Safety/MedWatch).
